Bausch + Lomb (NYSE:BLCO) Given a $19.00 Price Target at Citigroup

Bausch + Lomb (NYSE:BLCO) received a $19.00 target price from stock analysts at Citigroup in a research report issued to clients and investors on Tuesday,BayStreet.CA reports. The firm presently has a “buy” rating on the stock. Citigroup’s target price suggests a potential upside of 25.91% from the stock’s current price.

A number of other equities research analysts have also recently issued reports on the company. Barclays boosted their price objective on Bausch + Lomb from $17.00 to $20.00 and gave the company an “equal weight” rating in a research note on Thursday, February 19th. HC Wainwright lifted their target price on Bausch + Lomb from $17.00 to $20.00 and gave the company a “buy” rating in a report on Monday, February 23rd. Stifel Nicolaus set a $16.00 target price on Bausch + Lomb in a report on Thursday, February 19th. Wall Street Zen raised Bausch + Lomb from a “hold” rating to a “buy” rating in a report on Saturday, April 18th. Finally, Wells Fargo & Company lifted their target price on Bausch + Lomb from $17.00 to $18.00 and gave the company an “equal weight” rating in a report on Thursday, February 19th. Four equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $17.92.

Bausch + Lomb Stock Performance

Bausch + Lomb stock traded down $0.28 during midday trading on Tuesday, reaching $15.09. The stock had a trading volume of 774,052 shares, compared to its average volume of 436,457. Bausch + Lomb has a 12 month low of $11.22 and a 12 month high of $18.92. The firm’s 50-day moving average price is $16.07 and its 200 day moving average price is $16.60. The firm has a market capitalization of $5.38 billion, a PE ratio of -24.38, a P/E/G ratio of 0.48 and a beta of 0.58. The company has a quick ratio of 0.99, a current ratio of 1.53 and a debt-to-equity ratio of 0.78.

Bausch + Lomb (NYSE:BLCO) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.02. Bausch + Lomb had a positive return on equity of 3.60% and a negative net margin of 4.21%.The business had revenue of $1.24 billion for the quarter, compared to analysts’ expectations of $1.22 billion. During the same period in the previous year, the business posted ($0.07) EPS. The firm’s quarterly revenue was up 9.4% compared to the same quarter last year. As a group, research analysts predict that Bausch + Lomb will post 0.82 earnings per share for the current fiscal year.

Insider Transactions at Bausch + Lomb

In other Bausch + Lomb news, CEO Brent L. Saunders acquired 14,700 shares of the business’s stock in a transaction dated Friday, March 6th. The stock was bought at an average price of $17.14 per share, with a total value of $251,958.00. Following the completion of the acquisition, the chief executive officer owned 966,575 shares of the company’s stock, valued at $16,567,095.50. This trade represents a 1.54% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP A Robert D. Bailey acquired 14,600 shares of the business’s stock in a transaction dated Friday, March 6th. The shares were acquired at an average cost of $17.15 per share, with a total value of $250,390.00. Following the acquisition, the executive vice president directly owned 231,890 shares of the company’s stock, valued at $3,976,913.50. This represents a 6.72% increase in their position. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders acquired 33,300 shares of company stock valued at $570,868. 1.45% of the stock is owned by corporate insiders.

Institutional Trading of Bausch + Lomb

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. grew its stake in Bausch + Lomb by 729.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 2,322 shares of the company’s stock worth $30,000 after purchasing an additional 2,042 shares during the period. Caitong International Asset Management Co. Ltd grew its stake in Bausch + Lomb by 104.1% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,227 shares of the company’s stock worth $38,000 after purchasing an additional 1,136 shares during the period. Royal Bank of Canada grew its stake in Bausch + Lomb by 67.1% in the first quarter. Royal Bank of Canada now owns 3,657 shares of the company’s stock worth $58,000 after purchasing an additional 1,468 shares during the period. Wells Fargo & Company MN grew its stake in shares of Bausch + Lomb by 31.2% in the fourth quarter. Wells Fargo & Company MN now owns 5,903 shares of the company’s stock worth $101,000 after acquiring an additional 1,403 shares during the last quarter. Finally, Jones Financial Companies Lllp grew its stake in shares of Bausch + Lomb by 55.3% in the third quarter. Jones Financial Companies Lllp now owns 9,112 shares of the company’s stock worth $132,000 after acquiring an additional 3,246 shares during the last quarter. Hedge funds and other institutional investors own 11.07% of the company’s stock.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.